Impact of concomitant medication on clinical outcomes in patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors: a retrospective …
…, K Kirita, H Udagawa, K Goto, T Kawasaki… - Thoracic …, 2021 - Wiley Online Library
Background It has recently been suggested that concomitant medication may affect the clinical
outcome of patients treated with immune checkpoint inhibitors (ICIs). However, only a few …
outcome of patients treated with immune checkpoint inhibitors (ICIs). However, only a few …
[HTML][HTML] Comprehensive analysis of chemotherapeutic agents that induce infectious neutropenia
M Okunaka, D Kano, R Matsui, T Kawasaki, Y Uesawa - Pharmaceuticals, 2021 - mdpi.com
Chemotherapy-induced neutropenia (CIN) has been associated with a risk of infections and
chemotherapy dose reductions and delays. The chemotherapy regimen remains one of the …
chemotherapy dose reductions and delays. The chemotherapy regimen remains one of the …
[HTML][HTML] A case series on pain accompanying photoimmunotherapy for head and neck cancer
…, K Sugisaki, A Kawanobe, S Uozumi, T Kawasaki… - Healthcare, 2023 - mdpi.com
One of the most severe side effects of photoimmunotherapy (PIT) for head and neck cancer
is pain. As there are presently no detailed reports on pain and pain management in PIT, we …
is pain. As there are presently no detailed reports on pain and pain management in PIT, we …
[HTML][HTML] Evaluation of the expression profile of irinotecan-induced diarrhea in patients with colorectal cancer
M Okunaka, D Kano, R Matsui, T Kawasaki, Y Uesawa - Pharmaceuticals, 2021 - mdpi.com
Irinotecan (CPT-11) is widely used for the treatment of unresectable colorectal cancer in
combination with fluoropyrimidines, such as 5-fluorouracil and S-1. Diarrhea is one of the …
combination with fluoropyrimidines, such as 5-fluorouracil and S-1. Diarrhea is one of the …
Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib
…, H Okudera, M Tahara, T Kawasaki - SAGE Open …, 2020 - journals.sagepub.com
Objectives: Medical oncologists and pharmacists at our institution established an integrated
support program aimed at preventing unnecessary treatment interruption or dose reduction …
support program aimed at preventing unnecessary treatment interruption or dose reduction …
Interleukin 6/gp130 axis promotes neural invasion in pancreatic cancer
…, M Suzuki, M Narita, T Kawasaki… - Cancer …, 2022 - Wiley Online Library
Background Nerve invasion (N‐inv) is an important prognostic factor in pancreatic ductal
adenocarcinoma (PDAC). Elucidation of circulating N‐inv stimulators could provide deeper …
adenocarcinoma (PDAC). Elucidation of circulating N‐inv stimulators could provide deeper …
[HTML][HTML] Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: a multicenter …
…, M Yonemura, H Terakado, T Kawasaki… - Frontiers in …, 2022 - frontiersin.org
Background: Olaparib-induced anemia is a frequently occurring complication in patients
with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and is …
with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and is …
Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study
…, A Hosono, T Sasaki, T Kawasaki… - Japanese Journal of …, 2023 - academic.oup.com
Background Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are the standard treatment for
advanced hormone receptor-positive breast cancer. Although interstitial lung disease is a …
advanced hormone receptor-positive breast cancer. Although interstitial lung disease is a …
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil …
…, H Daiko, S Fujii, T Kojima, K Itoh, T Kawasaki - Cancer Chemotherapy …, 2020 - Springer
Purpose The combination of docetaxel, cisplatin and 5-fluorouracil (DCF) is a newly
developed chemotherapy regimen for esophageal cancer. Severe neutropenia is dose-limiting …
developed chemotherapy regimen for esophageal cancer. Severe neutropenia is dose-limiting …
The impact of the COVID‐19 pandemic on perioperative chemotherapy for breast cancer
…, N Matsubara, Y Naito, A Hosono, T Kawasaki… - Cancer …, 2023 - Wiley Online Library
Background Since it was first reported in December 2019, coronavirus disease 2019 (COVID‐19)
spread rapidly across the globe resulting in a pandemic. As of August 2022, seven …
spread rapidly across the globe resulting in a pandemic. As of August 2022, seven …